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ABSTRACT
A biologically important human gene, cyclo-
oxygenase-2 (COX-2), has been proposed to be regu-
lated at many levels. While COX-1 is constitutively
expressed in cells, COX-2 is inducible and is upregu-
lated in response to many signals. Since increased
transcriptional activity accounts for only part of the
upregulationofCOX-2,wechosetoexploreotherRNA
processing mechanisms in the regulation of this
gene. We performed a comprehensive bioinformatics
survey, the first of its kind known for human COX-2,
which revealed that the human COX-2 gene has alter-
native polyadenylation (proximal and distal sites)
and suggested that use of the alternative polyadeny-
lation signals has tissue specificity. We experi-
mentally established this in HepG2 and HT29 cells.
We used an in vivo polyadenylation assay to examine
the relative strength of the COX-2 proximal and
distal polyadenylation signals, and have shown
that the proximal polyadenylation signal is much
weaker than the distal one. The efficiency of utiliza-
tion of many suboptimal mammalian polyadenyla-
tion signals is affected by sequence elements
locatedupstreamoftheAAUAAA,knownasupstream
efficiency elements (USEs). Here, we used in vivo
polyadenylation assays in multiple cell lines to
demonstrate that the COX-2 proximal polyadenyla-
tion signal contains USEs, mutation of the USEs
substantiallydecreasedusageoftheproximalsignal,
and that USE spacing relative to the polyadenyla-
tion signal was significant. In addition, mutation of
the COX-2 proximal polyadenylation signal to a more
optimal sequence enhanced polyadenylation effici-
ency 3.5-fold. Our data suggest for the first time that
alternative polyadenylation of COX-2 is an important
post-transcriptional regulatory event.
INTRODUCTION
Cyclooxygenases (COX) are the key and rate-limiting
enzymes in the production of prostaglandins [reviewed in (1)
and references therein]. The ﬁrst steps in prostanoid synthesis
are the release of arachidonic acid from membrane phosop-
holipids by phospholipases and conversion to prostaglandin
H2 by COX. Prostaglandins play a role in many biological
processes, including but not limited to inﬂammation, bone
formation, wound healing and pain perception. Inﬂammatory
cells as well as other types of cells, including ﬁbroblasts and
epithelial cells produce prostaglandins (2,3).
Two separate COX genes have been identiﬁed, COX-1 and
COX-2 (4–10). A spliced variant of COX-1 (COX-3) has also
been identiﬁed (11). The proteins that these genes encode
are  60% identical at the amino acid level. In contrast, the
30-untranslated regions (30-UTRs) of COX-1 and COX-2 are
highly divergent. The most striking difference between these
genes is in their regulation of expression; COX-1 is constit-
utivelyexpressedwhileCOX-2 isstronglyinducedinresponse
to activation by hormones, pro-inﬂammatory cytokines,
growth factors, oncogenes, carcinogens and tumor promoters
(1–3,12–15).
The physiological or pathological outcomes of COX-2
activity depend upon its level of expression. COX-2 over-
expression is associated with a number of conditions, includ-
ing cancer, rheumatoid arthritis, seizures and inﬂammatory
disorders [reviewed in (1,16–22)]. In addition, COX-2 upregu-
lation contributes to pain; indeed, inhibition of COX-2
enzymatic activities is responsible for the anti-inﬂammatory
properties of aspirin, indomethacin, ibuprofen and related
NSAIDs,suchasVioxx(Rofecoxib)andCelebrex(Celecoxib).
Molecular events leading to overexpression of COX-2 have
not been deﬁnitively characterized. Some studies have clearly
demonstrated increased levels of COX-2 mRNA in colorectal
adenomas, colon cancer cell lines, adenocarcinomas, gastric
cancer, breast cancer, certain ovarian and prostate cancers,
and non-small lung cancer (22–33). Enhanced COX-2 mRNA
transcription may play a role but enhanced COX-2 protein
expression most probably requires post-transcriptional gene
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doi:10.1093/nar/gki544regulation events, such as are mediated through mRNA pro-
cessing and mRNA turnover. Indeed, the kinetics of trans-
criptional activation alone cannot account for the sustained
induction of COX-2 mRNA by interleukin 1 in vascular endo-
thelial cells (14).
The 30 end of nearly every fully processed eukaryotic
mRNA has a poly(A) tail, which has been suggested to inﬂu-
ence mRNA stability, translation and transport (reviewed in
(34–37)]. Polyadenylation is a two-step process [reviewed in
(38–41) and references therein], ﬁrst involving speciﬁc endo-
nucleolytic cleavage (42) at a site determined by binding of
polyadenylation factors. The second step involves polymer-
ization of the adenosine (A) tail to an average length of  200
residues. Most mammalian polyadenylation signals contain
the consensus sequence AAUAAA or a close variant between
10 and 35 nt upstream of the actual cleavage and polyadenyla-
tion site. AAUAAA is associated with a frequency of  53%
of all human polyadenylation signals and  59% of all mouse
polyadenylation signals (43). This hexamer sequence serves
as a binding site for the basal polyadenylation factor cleav-
age and polyadenylation speciﬁcity factor (CPSF) (38–41).
Sequences  14–35 nt downstream of the polyadenylation
signal are also known to be involved in directing polyadenyla-
tion by serving as a binding site for the basal polyadenyla-
tion factor cleavage stimulation factor (CstF) [(38–41,44–52)
and references therein]. Elements upstream of the AAUAAA
sequences, known as upstream efﬁciency elements (USEs),
have also been characterized that can enhance polyadenyla-
tion efﬁciency, and have been identiﬁed in viral and cellular
systems [(53–66) and references therein]. Spacing between
the AAUAAA and the USE signiﬁcantly inﬂuences USE efﬁ-
ciency in enhancing polyadenylation (65). Although USEs are
polyadenylation efﬁciency elements, they may also provide
additional functions in proper processing.
As has been appreciated in recent years, 30 end formation
is interconnected to mRNA processing events, as well as to
mRNA transcription and transcription termination (40,67–69).
This interconnection and execution of a functional mRNA
likely results from recognition and utilization of cis- and
trans-acting signals.
The 30-UTR of an mRNA can have a major inﬂuence on
developmental and tissue-speciﬁc regulation of gene expres-
sion. In fact, the 30-UTR has recently been called ‘a molecular
hotspot for pathology’ (70). Regulation of gene expression
through the 30-UTR can include alternative polyadenylation,
translational control and differential mRNA stability. Prelim-
inary evidence suggests that regulated polyadenylation and
mRNA stability may play a pivotal role in COX-2 expression.
The COX-2 gene is made up of 10 exons; the 30-UTR is
contained within exon 10 (71). The COX-2 30-UTR is larger
than average,encompassing  2.5kb,andhasmanyinteresting
features. It has several polyadenylation signals, only two of
which are commonly used, resulting in mRNAs of  2.8 kb
using the proximal (with regard to the stop codon) poly-
adenylation signal or  4.6 kb using the distal polyadenylation
signal (Figure 1). The proximal polyadenylation signal has a
non-consensus CPSF binding site (AUUAAA) yet it is used. It
is likely that regulation occurs here, resulting in two mRNAs
with different RNA metabolism. Curiously, the mRNA that
uses the proximal polyadenylation signal contains putative
USEs which are similar in sequence and location to those
we and others described previously (64–66). The 30-UTR
also has 22 repeats of an AU-rich motif resembling those
known to be involved in regulation of mRNA stability
(72,73). Recent studies have found that HuR, or a close vari-
ant, binds to these AU-rich elements (AREs) (74–76). Other
studies have shown additional RNA binding proteins also may
bind to the COX-2 30-UTR (77–79). Additionally, it has been
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Figure 1. Schematic representation of the human COX-2 30-UTR. Diagram of the 30-UTR of the human COX-2 gene highlighting the major polyadenylation signals;
resulting mRNAs are also depicted. Putative auxiliary USEs are represented by hatched boxes; checkered boxes represent CstF binding sites; AREs are represented by
dotted ovals. Bottom: sequence of a portion of the COX-2 proximal polyadenylation signal. Putative USEs are italicized, underlined and noted above the sequence.
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a role in COX-2 polyadenylation site choice (80,81). The
signiﬁcance of the different tissue distributions of these
isoforms has not yet been addressed, and most probably
will provide signiﬁcant revelations with regard to COX-2
expression control.
Alternative polyadenylation of the COX-2 30-UTR results
in two mRNAs differing only in their 30 ends. Therefore,
the choice of a particular polyadenylation site likely involves
speciﬁc cis- and trans-acting factors, resulting in RNAs with
different metabolism, and ultimately will inﬂuence the cyto-
plasmic fate of the mRNA. This study examines the regula-
tion of alternative 30 end formation in the human COX-2
pre-mRNA. We demonstrate that alternative polyadenylation
does occur in the COX-2 mRNA and that the two major,
utilized polyadenylation signals (proximal and distal) are
different in strength and composition. We also show that
alternative polyadenylation of the COX-2 mRNA occurs in a
tissue-speciﬁc fashion in cells that endogenously overexpress
COX-2. The proximal polyadenylation signal contains
auxiliary USEs that are important for its efﬁcient usage.
These experiments suggest that alternative polyadenylation
of COX-2 mRNA is an important level of gene expression
regulation, because polyadenylation signal choice will include
or exclude additional regulatory elements that may inﬂuence
the metabolic fate of the mRNA.
MATERIALS AND METHODS
Plasmids
Primers for PCR to amplify the proximal and distal polyade-
nylation signals of the human COX-2 30-UTR were prepared
by the Molecular Resource Facility of UMDNJ-NJMS, and
had the sequences as listed in Supplementary Table 2.
The COX-2 proximal and distal primers contained BamHI
(forward) and PstI (reverse) restriction sites to allow insertion
intoappropriatelydigestedvectors.HumangenomicDNAwas
used as a template to amplify by PCR the appropriate COX-2
proximal and distal polyadenylation signals and ﬂanking
sequences for insertion into pGem4 and pCbS vectors. The
pCbS vector (a gift from David Fritz, UMDNJ) (64) has a
multiple cloning site downstream of the CMV promoter and
upstream of the bovine growth hormone (BGH) polyadenyla-
tion signal. This vector also includes intron 1 of the rabbit
b-globin gene accompanied by the splice donor and acceptor
sites. Thus, pCbS-proximal and pCbS-distal were created.
The USE mutants, the hexamer mutant and the non-speciﬁc
mutant were made by PCR-based site-directed mutagenesis
using the Stratagene QuikChange kit as per the manufacturer’s
protocols using the pCbS-proximal vector as the template. The
USE and non-speciﬁc mutant were designed to create BglII
restriction sites for ease in screening. The COX-2 proximal 50
deletion (D) mutant was made by PCR using primers described
in Supplementary Table 2. This construct is lacking 115 bases
upstream of the COX-2 proximal polyadenylation signal.
The USE mutant 1 has the sequence AAGATCAAA instead
of the wild-type sequence AATTTGAA; the USE mutant 2
has the sequence AAGATCTAA instead of the wild-type
sequence AATTTCTAA; the USE mutant 3 has the sequence
GAGATCTTA instead of the wild-type GATTTCTTA.
The USE mutants 1,3 and 2,3 had both USEs mutated as
described above.
The pCbS-proximal–distal-BGH construct was made in the
following manner. The COX-2 distal polyadenylation signal
was removed from pCbS-distal by BamHI and PstI, then the
ends were blunted and inserted into pCbS-proximal which
had been digested with EcoRV. Therefore, pCbS-proximal–
distal-BGH has three polyadenylation signals in tandem.
The pCbS-proximal–distal construct was made by digesting
pCbS-proximal–distal-BGH with XhoI and KpnI to remove
the BGH polyadenylation signal. Therefore, pCbS-proximal–
distal has both COX-2 polyadenylation signals in tandem.
All constructs were transformed into Escherichia coli XL1-
Blue cells. Positive clones were sequenced and assayed for
expression of the appropriately sized insert. Constructs were
veriﬁedbysequencing(MolecularResourceFacility,UMDNJ-
NJMS). SVL RNA was used as described previously (66).
Rapid site-directed mutagenesis using two
PCR-generated DNA fragments
The USE double (USE mut 1,2) and triple (USE mut 1,2,3)
mutations were generated by standard PCR using KOD poly-
merase and using the upstream (50) wild-type COX-2 proximal
primer containing a BamHI restriction site and a downstream
primer (30; USE 1,2 R) containing the respective site-directed
mutagenic base pair changes. Then the upstream mutagenic
primer (50; USE 1,2 F) was used in standard PCR using KOD
polymerase and the wild-type COX-2 proximal downstream
primer (30) containing a PstI restriction site. The USE 1,2 mut
was prepared using COX-2 proximal wild-type DNA template
in the PCR, while the USE 1,2,3 mut was prepared using USE
3 mut DNA template. The products of the above two sets of
PCR steps were re-ampliﬁed using the 50 and 30 wild-type
COX-2 proximal primers and the resulting 268 bp fragment
was cloned into the BamHI/PstI sites of the pCbS vector.
Mammalian cell culture
HeLa, MDA-MD231 and HepG2 cells were maintained in
DMEM (Life Technologies) supplemented with 10% fetal
bovine serum (Sigma) and 1% penicillin–streptomycin (Life
Technologies). HT29 cells were maintained in RPMI-1640
Medium (Life Technologies) supplemented with 10% fetal
bovine serum and 1% penicillin–streptomycin.
Transfection
HeLa or MDA-MB-231 cells (7 · 10
5 cells/well) were seeded
in60 mm plates  12 hbefore transfection. When cells reached
80% conﬂuency, they were transfected using LT-1 reagent
(Mirus). Plasmid DNA (2.8 mg) was diluted in 180 mlo f
serum-free medium to which 6 ml of LT-1 was added and
the mixture was incubated at room temperature for 20 min.
Following the addition of 1 ml complete medium to the trans-
fection mixture, the medium on the cells was removed and
replaced with the entire transfection cocktail. After 24 h, cells
were washed once with 1· phosphate-buffered saline (PBS).
Cells were scraped and collectedinto 1ml PBS and transferred
into microcentrifuge tubes. Cells were then centrifuged at
7000 r.p.m. for 5 min (4500 g in an Eppendorf microcentri-
fuge). The PBS was aspirated and total RNA was extracted
immediately from the cell pellet as described below.
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To determine polyadenylation signal use in vivo, total RNA
from transfected cells was assayed by RNase protection.
Total RNA was extracted from the cell pellet using either
the TRIZOL method (Invitrogen) or the RNeasy Mini Kit
(Qiagen) according to the manufacturer’s spin protocol for
isolationoftotal RNA fromanimal cells. ForRNaseprotection
assay reactions, 5 mg of total RNA was used per reaction.
Probe RNA for the in vivo polyadenylation assay was prepared
as described below. The reporter and/or endogenous RNA
levels were determined by RNase protection using the RPAIII
kit (Ambion Inc., Austin, TX). The RNA was then analyzed
on 5% polyacrylamide–8 M urea gels as described previously
(64). The ratio of the reporter assay and endogenous band
detection was quantiﬁed using a Typhoon PhosphorImager
and ImageQuant software.
In vitro transcription of RNA substrates
RNA transcripts for in vitro polyadenylation, in vivo poly-
adenylation assays and RNase protection assays were synthes-
ized by use of SP6 or T7 RNA polymerase according to the
supplier (Promega) in the presence of 50 mCi of [a-32P]UTP
(Amersham Pharmacia Biosciences or Perkin Elmer Bio-
sciences). RNAs were puriﬁed from 5% polyacrylamide–
8 M urea–TBE gels by overnight crush elution in high salt
buffer (0.4 M NaCl, 50 mM Tris, pH 8.0 and 0.1% SDS). Prior
to use in reactions, eluted RNAs were ethanol precipitated and
resuspended in water.
Linearization of all pCbS and pGEM4 DNA constructs
at the BamHI site and transcription using T7 RNA polymerase
as mentioned above generates antisense RNAs. Transcrip-
tion of CbS COX-2 ‘proximal’ yielded a 610 base RNA, of
COX-2 ‘distal’ an 854 base RNA for use in the in vivo poly-
adenylation assay. SVL was linearized with DraI as described
previously (66).
In vitro polyadenylation assays
HeLa nuclear extracts were prepared as described [(64) and
references therein] using HeLa cells purchased from the
National Cell Culture Center (Minneapolis, MN) or grown in
our laboratory. In vitro polyadenylation assays using HeLa
nuclear extract, the SV40 late polyadenylation signal pre-
mRNA and COX-2 USE RNA or non-speciﬁc oligoribonuc-
leotides were performed as described previously (64). Brieﬂy,
the in vitro polyadenylation reactions contain a ﬁnal concen-
tration of 58% (v/v) HeLa nuclear extract, 16 mM phospho-
creatine (Sigma), 0.8 mM ATP (Amersham Biosciences),
2.6% polyvinyl alcohol, and 1 · 10
5 c.p.m. of
32P-labeled SVL
substrate RNA ( 50 fmol) in a total volume of 12.5 ml. These
reactions are incubated at 30 C for 1 h. The COX-2 USE 3
RNA oligoribonucleotide was synthesized by Dharmacon
Research, Inc. (Lafayette, CO) and had the sequence UUG-
UUUGAUUUCUUAAAGU.Thenon-speciﬁcRNAoligoribo-
nucleotide was described previously (64).
Immunoblot analysis
Cell lysates were prepared by incubating 1.5 · 10
6 cells on ice
for 30 min in a solution containing 1% NP-40, 150 mM NaCl
and 50 mM Tris–HCl (pH 8.0), plus phenylmethylsulfonyl
ﬂuoride (50 mg/ml), leupeptin, aprotinin and pepstatin A
(each at 1 mg/ml). Protein from cleared lysate (75 mg) was
separated by 10% SDS–PAGE, then blotted onto nitrocellu-
lose membrane and blocked in 5% non-fat dry milk. Primary
antibody incubations were performed at a dilution of 1:100
in blocking solution for 3 h at room temperature. Mouse
anti-human COX-2 monoclonal antibody and recombinant
humanCOX-2proteinwerepurchasedfromCaymanChemical
(Ann Arbor, MI). Goat-antimouse horseradish peroxidase-
conjugated secondary antibody (ICN) was used at a dilution
of 1:5000 for 1 h at room temperature. Visualization of bound
antibodies was accomplished through chemiluminescence
using an ECL kit (Amersham Pharmacia Biosciences) and
autoradiography.
Bioinformatics
Expressed sequence tag (EST) sequences corresponding to the
human COX-2 gene and their tissue information were obtained
from dbEST (March 2004 version; National Center for Bio-
technology Information, NCBI), according to the UniGene
database (March 2004 version; NCBI). Sequences were
aligned to the human genome and polyadenylation sites were
determined by using a method described previously [(43) and
references therein]. ESTs with poly(A) tail sequence were
used to infer polyadenylation sites.
Statistical analyses
Results are expressed as –SD of the mean, and analyses
were performed by two-sample one-tailed Student’s t-test.
P-values <0.05 were considered signiﬁcant.
RESULTS
EST surveys suggest existence of multiple
polyadenylation signals for the human COX-2
gene with tissue specificity
Because alternative polyadenylation is potentially a key regu-
lator of human COX-2 expression, we systematically invest-
igated the mechanism controlling alternative 30 end formation.
Using a bioinformatics approach, we have surveyed the
current EST database for human COX-2 mRNAs that would
represent utilization of either the proximal or the distal COX-2
polyadenylationsignal.UsingESTswithpoly(A)tailsequence
(see Materials and Methods; B. Tian and C. S. Lutz, unpub-
lished data), we identiﬁed three COX-2 polyadenylation sig-
nals, named proximal 1, proximal 2 and distal, respectively
(Table 1, top). The closed diamonds represent ESTs contain-
ing poly(A) tail sequence. The open circles denote ESTs
thatdonothave poly(A)tailsequence.Sincetheseopencircles
are located after proximal 2, they indirectly support the use
of the distal polyadenylation signal, assuming there is no other
poly(A) signal between proximal 2 and distal. The distance
between proximal 1 and proximal 2 is  400 nt, and between
proximal 2 and distal is a little less than 2000 nt. Since
proximal 1 lacks a deﬁnable CstF binding site and previous
northern blot data only support transcript sizes resulting from
proximal 2 and distal signal usage (80,81), we focused on
proximal 2, which we will refer to simply as ‘proximal’
throughout the rest of our study. The distance between prox-
imal and distal from this EST survey is in good agreement
2568 Nucleic Acids Research, 2005, Vol. 33, No. 8with those reported in previous studies [(80,81) and Figure 1].
Also in Table 1 are cDNA library IDs for the ESTs found (ﬁrst
column in Table 1) and tissue and organ information if known
on the biological source of the cDNA libraries (last two
columns in Table 1). Use of the COX-2 proximal and distal
polyadenylation signals are noted by the numbers of ESTs that
appeared from each library.
To our knowledge, this is the ﬁrst data for COX-2 examined
in this manner. Moreover, our data are comprehensive; all
available ESTs corresponding to human COX-2 were used.
Table 1. Expressed sequence tag survey result of COX-2 polyadenylation signals
Proximal 1 Proximal 2 Distal
0 500 1,000 1,500 2,000 2,500
LIB_ID P1 P2 D Di Organ Tissue
9821 1 1 1 Pancreas Islets of Langerhans
12072 1 1 Lung Alveolar macrophage
423 1 Senescent fibroblast
9692 1 Human skeletal muscle
1410 3 2 3 Prostate
1184 1 Pooled
12540 1 Liver
12798 1
9691 2
464 1
537 1 Lung Lung carcinoma
938 1 1 Colon Tumor
1045 1 Kidney
1449 1 1 Stomach Poorly differentiated adenocarcinoma with signet ring cell features
1461 1 Uterus Well-differentiated endometrial adenocarcinoma, seven pooled tumors
1661 1 Lung Squamous cell carcinoma, poorly differentiated (four pooled tumors,
including primary and metastatic)
2298 1 Lung Two pooled squamous cell carcinomas
2460 1 Whole blood Myeloid cells, 18 pooled CML cases, BCR/ABL rearrangement positive,
includes both chronic phase and myeloid blast crisis
5488 1 Trabecular meshwork
8613 1 Blood Lymphocyte
10398 1 Lung Primary lung epithelial cells
10411 1 Lung Metastatic chondrosarcoma
10413 1 1 Left pelvis Chondrosarcoma
10416 1 Left pelvis Chondrosarcoma
10424 1 Placenta Placenta
13024 1
13833 1
271 2 1 Placenta
910 2 1 Prostate Normal prostate
2457 2 1 Genitourinary tract Two pooled high-grade transitional cell tumors
313 3
655 1 Bone
787 1 Prostate
1076 1 Lung Carcinoid
2393 1
4723 1
4761 2 Breast_normal
5191 1 Head_and neck
5566 1 Bone marrow From chronic myelogenous leukemia
5949 1 Brain Glioblastoma
6975 1 Bone marrow
8684 1 Skin
10426 1 Mixed
10925 1 Left pelvis Chondrosarcoma grade II
11912 1 Lung Human lung epithelial cells
13018 1
Top:genomicsequenceofCOX-230-UTRcontainingthreepolyadenylationsignalsisdepictedschematically.Thepositionofproximal1isarbitrarilysetas0.Closed
diamondsdenotethelocationsofpoly(A)signalssupportedbyESTswithpoly(A)tailsequence.Opencirclesarethelocationsofthe30endofESTswithoutpoly(A)tail
sequence.Bottom:LIB_IDcorrespondstocDNAlibraryIDinthedbESTdatabase.P1,proximal1;P2,proximal2;D,distal;andD1,distalsupportedbyESTswithout
poly(A) tail sequence (explained in the text).
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tion signals are used in vivo; (ii) there are different tissue
patterns/distributions and (iii) this is a much larger-scale ana-
lysis than has previously been reported. Importantly, these
tissue-speciﬁc distribution patterns and the polyadenylation
signals utilized closely match smaller scale, reported tissue
speciﬁcity (80,81), with use of the proximal form notably
predominating liver, while the distal form notably predomin-
ates in colon. Our data underscore the biological relevance of
our study and highlight the need for understanding the mech-
anisms of regulation that are involved.
Endogenous COX-2 mRNAs are polyadenylated at
different sites in cell lines representing different tissues
To further evaluate the biological usage of both polyadenyla-
tion signals with regard to the tissue speciﬁcity noted by our
bioinformatics analysis, we chose two established human
cancer cell lines, HT29 (colon) and HepG2 (liver). Like many
colon cancer-derived cell lines (75), HT29 cells constitut-
ively express COX-2 since endogenous COX-2 protein can
be readily detected by western blotting in HT29 extracts
(Figure 2A, lane 2). The constitutive expression of COX-2
in hepatocellular carcinoma cells such as HepG2 has been
debated in the literature. In our hands, COX-2 protein was
detected in HepG2 extract indicating that COX-2 is expressing
in this hepatocellular carcinoma cell line (Figure 2A, lane 3).
The levels of endogenous COX-2 protein appear to be lower
in HepG2 cells than in HT29 cells. As a loading control, we
probed the same western blot with an antibody speciﬁc for
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and
found GAPDH to be equivalent in each lane (data not shown).
It has been reported that the distal COX-2 polyadenylation
signal is used in primary colon samples and that the proximal
polyadenylation signal is used in liver samples as assayed by
northern blots, but this conclusion was based purely on tran-
script size (81). We therefore decided to perform our assay
based on a more precise method of analyzing polyadenylation
signal usage. This assay allows us to speciﬁcally identify use
of the proximal and distal polyadenylation signals (Figure 2B;
see also Figure 1). Total RNA was extracted from HT29 and
HepG2 cells and this RNA was used in standard RNase
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Figure 2. Tissue-specificalternativepolyadenylationofCOX-2inHT29andHepG2cells.(A)Westernblotof75mgtotalproteincellextractfromHT29andHepG2
cells using an anti-COX-2 monoclonal antibody. Lane 1, 1 mg recombinant COX-2 protein. (B and C) RNase protection assays using endogenous RNA from HT29
(B) and HepG2 (C) cells along with COX-2 proximal and/or distal probes. The data shown in (B), lane 2, illustrate that HT29 cells primarily use the COX-2 distal
polyadenylation signal. (C) HepG2 cells utilizing the COX-2 proximal signal in lane 1 and the distal signal in lane 2. The band corresponding to utilization of the
COX-2proximalpolyadenylationsignalismarkedwithanasterisk;thebandcorrespondingtoutilizationoftheCOX-2distalpolyadenylationsignalismarkedwith
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2570 Nucleic Acids Research, 2005, Vol. 33, No. 8protection assays using speciﬁc COX-2 proximal and distal
probes. pGEM4-distal and pGEM4-proximal antisense probes
protected the speciﬁc bases corresponding to the proximal and
distal polyadenylationsignals.ThedatainFigure2Bshow that
HT29 cells primarily use the COX-2 distal polyadenylation
signal, giving a protected fragment of 235 bp. HepG2 cells
utilize both the COX-2 proximal and distal signals, giving pro-
tected fragments of 168 and 235 bp, respectively (Figure 2C).
The proximal probe is also able to bind to and protect a 268 bp
fragment in the distal mRNA, which corresponds to the entire,
uncleaved and unused proximal polyadenylation signal (lane 1
in Figure 2B and C). The larger size reﬂects the fact that
sequences downstream of the proximal cleavage site are con-
tained in the distal mRNA. Our data reveal that there is regu-
lated, differential, tissue-speciﬁc polyadenylation of COX-2.
In vivo polyadenylation of COX-2 using reporter assays
After conﬁrming that both COX-2 polyadenylation signals
are used in vivo, we next applied our in vivo polyadenylation
assays (64) to address directly the mechanism controlling use
of the COX-2 proximal and distal polyadenylation signals. We
ﬁrst addressed how the suboptimal AUUAAA proximal COX-
2 polyadenylation signal behaved in our system. The apparent
weakness of this polyadenylation signal was postulated based
uponitsdivergencefromtheconsensusAAUAAACPSFbind-
ing site. We cloned a 268 bp fragment by PCR including the
human COX-2 proximal polyadenylation signal and ﬂanking
sequences into our two polyadenylation signal reporter vector
pCbS, diagrammed in Figure 3A. In this series of experiments,
the proximal signal was inserted into the signal 1 site while the
BGH signal occupied the signal 2 site. This pCbS-COX-2-
proximal construct was then transformed into HeLa or MDA-
MB-231 (breast cancer) cells. Total RNA was isolated after 24
h, RNase protectionassays were performed usingthe antisense
probe to the pCbS-COX-2-proximal construct (Figure 3A),
and the results were quantiﬁed using a PhosphorImager and
ImageQuant software. RNase protection assays will produce a
protected fragment of 168 bases if the COX-2 proximal poly-
adenylation signal is used; utilization of the BGH signal will
produce a protected fragment of 410 bases. We found that
polyadenylation at the COX-2 proximal signal compared
with that at the BGH signal occurred in a ratio of 1:3, indic-
ating that the proximal COX-2 signal is indeed suboptimal
(Figure 3B, lane 4 and Figure 3C).
We next compared polyadenylation using the COX-2 distal
polyadenylation signal to BGH by the same type of assay. We
cloned a 454 bp fragment by PCR containing the COX-2 distal
polyadenylation signal into the pCbS vector, with the COX-2
distal signal occupying the polyadenylation signal 1 site in the
reporter vector. Use of the COX-2 distal polyadenylation
signal in the RNase protection assay will protect a fragment
of 235 bases. Because the distal polyadenylation signal has
a consensus AAUAAA, we predicted that this signal would be
stronger than the proximal polyadenylation signal of COX-2.
Indeed, the COX-2 distal polyadenylation signal was stronger
than the COX-2 proximal signal, and was used  45% of the
time compared with polyadenylation at the BGH signal of
 55% (Figure 3B, lane 5 and Figure 3D). In this set of experi-
ments, the band corresponding to BGH migrated slightly
faster than expected. This result was reproducible in this
assay, and has been observed previously using the same
assay and same vector (64). These assays were performed
in HeLa or MDA-MB-231 cells where there is no detectable
endogenous COX-2 protein or mRNA (data not shown). These
data demonstrate that although both COX-2 polyadenylation
signals are used, the COX-2 proximal signal is indeed weak
and the COX-2 distal signal is stronger as compared with the
internal control.
Since the COX-2 polyadenylation signals are normally in
tandem in the COX-2 30-UTR, and therefore may be in com-
petition with each other, we measured their relative use in a
similar assay as described above. Here, the COX-2 proximal
and distal polyadenylation signals were both placed in their
respective order in the pCbS reporter plasmid while keeping
the BGH polyadenylation signal intact (pCbS-proximal-distal-
BGH). After transfection into HeLa cells, RNase protection
assays were performed as described above. In this context, the
relative use of COX-2 proximal signal was 14.3%, the relative
use of the COX-2 distal signal was 53.5%, and the relative use
of the BGH polyadenylation signal was 32.2%, giving a ratio
of proximal/distal/BGH of 1:3.8:2.3 (data not shown). When
the BGH polyadenylation signal was removed to produce
a tandem construct (pCbS-proximal-distal), transfected into
HeLa or MDA-MB-231 cells, RNA isolated and RNase pro-
tection assays performed, the ratio of proximal/distal poly-
adenylation signal usage was 1:3, not appreciably different
from when the BGH was present (Figure 3B, lane 7 and
Figure 3E). Note that the creation of the pCbS-proximal-distal
construct caused the resulting protected fragments to differ in
size slightly from the results obtained using either the pCbS-
proximal or the pCbS-distal alone. These data demonstrate
that the COX-2 proximal polyadenylation signal does not
compete signiﬁcantly with the distal polyadenylation signal
in tandem.
Effect of mutation of core and auxiliary polyadenylation
elements in the suboptimal COX-2 proximal
polyadenylation signal
Since the COX-2 proximal core polyadenylation signal
is AUUAAA, and therefore differs from the consensus
AAUAAA, we showed that it was suboptimal in vivo
(Figure 3B, lanes 4 and 7). Previous in vitro studies in the
Wickens and Shenk laboratories had mutated the consensus
AAUAAA to every base at each position (82,83). These stud-
ieshadshowninvitrothat whileAUUAAAworkedbetterthan
any other derivative of AAUAAA, it still did not perform
as well as the consensus AAUAAA. To further prove this
in vivo, we mutated the AUUAAA to the consensus sequence
AAUAAA using site-directed mutagenesis (see Figure 4A
for diagram). We then measured polyadenylation signal use
(relative to BGH polyadenylation signal use) by RNase pro-
tection assays as described above. Here, we have calculated
fold-induction at the proximal polyadenylation signal; so util-
ization at the wild-type proximal signal was set at a value of 1.
We found that this single change, AUUAAA to AAUAAA
mutation, enhanced polyadenylation by 3.5-fold over the level
of polyadenylation at the COX-2 proximal polyadenylation
signal (Figure 4B), thus acting as a positive mutant. Similar
resultswerefoundusingMDA-MB-231cells(datanotshown).
These results conﬁrmed directly for the ﬁrst time in vivo
Nucleic Acids Research, 2005, Vol. 33, No. 8 2571that the difference between an ‘optimal’ AAUAAA and
a ‘suboptimal’ AUUAAA core polyadenylation signal is
operationally real.
Polyadenylation efﬁciency can be enhanced by the presence
of auxiliary elements located upstream of the CPSF binding
site, known as USEs (64–66). Sequences upstream of the
COX-2 proximal polyadenylation signal that we identiﬁed
bear striking similarity to the consensus UAU2–5GUNA USE
sequence previously studied in our laboratory. The COX-2
USEs are located 58, 49 and 6 bases upstream of the proximal
polyadenylation signal (Figure 4A). We predicted that these
putative USEs would affect polyadenylation efﬁciency of the
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2572 Nucleic Acids Research, 2005, Vol. 33, No. 8suboptimal COX-2 proximal polyadenylation signal. In order
to experimentally address this prediction, we mutated the
USEs in the context of our in vivo polyadenylation construct.
Mutants were prepared by PCR-based site-directed muta-
genesis in each of the three putative USEs, as well as a
non-speciﬁc mutant in a non-USE region upstream of the
COX-2 proximal polyadenylation signal (Figure 4A). These
constructs were then transfected into HeLa (or MDA-MB-231
cells; data not shown), total RNA was isolated and RNase
protection assays were performed as described above. The
results are shown in Figure 4C. Mutation of each USE was
increasinglymoredeleteriousastheUSEmutationapproached
the suboptimal core polyadenylation hexamer element
AUUAAA, with USE 3 mutation alone decreasing in vivo
polyadenylation to approximately half of the wild-type
level (Figure 4C). Mutation of the USEs in duplicate (USE
1,2 mut; USE 2,3 mut;USE 1,3 mut)resulted inapproximately
the same level of reduced polyadenylation efﬁciency as the
USE 3 mut alone (Figure 4C). However, the triple USE
mutation (USE 1,2,3 mut) resulted in a signiﬁcant decrease
in polyadenylation signal utilization (Figure 4C). Deletion of
the entire USE-containing region in the 50D mutant almost
abolished polyadenylation at the COX-2 proximal poly-
adenylation signal (Figure 4C). Taken together, these data
suggest that the USEs may have additive or synergistic
effects. These data also suggest that the USEs are important
polyadenylation efﬁciency elements in the COX-2 proximal
polyadenylation signal, and perhaps ensure that the proximal
signal is utilized.
USE competition for polyadenylation suggests that a
trans-acting factor could be influencing polyadenylation
at signals containing USEs
To further deﬁne a functional role of the USEs as auxiliary
efﬁciency elements, we performed in vitro polyadenylation
assays using speciﬁc competitors. Previously, we have shown
that in vitro polyadenylation reactions containing an SV40
late polyadenylation signal substrate RNA (SVL) could be
inhibited speciﬁcally by oligoribonucleotides representing
the SV40 USE motifs (66), and that polyadenylation in vitro
of human COL1A2 substrate RNA can be inhibited by a
COL1A2 USE oligoribonucleotide (64). We now prepared
an oligoribonucleotide that represents COX-2 USE 3, and
added this oligoribonucleotide to in vitro polyadenylation
reactions containing HeLa nuclear extract and a
32P-labeled
SVL prepared by in vitro transcription using SP6 polymerase.
This substrate RNA was chosen because it works well for
in vitro polyadenylation, and because the USEs in SV40 are
similar to those found in the proximal COX-2 polyadenylation
signal. The data are shown in Figure 5A and B. Figure 5A
demonstrates graphically that the COX-2 USE oligoribonuc-
leotide speciﬁcally inhibited SVL polyadenylation in vitro,
whereas a non-speciﬁc oligoribonucleotide had no signiﬁcant
effect on SVL polyadenylation. An additional non-speciﬁc
oligonucleotide also had no effect (data not shown) (64).
Figure 5B shows representative experiments. Lane 1 in
Figure 5B, both upper and lower panels, represents a reaction
performed in the absence of competitor oligoribonucleotides
and demonstrates that the SVL RNA was efﬁciently poly-
adenylated in the in vitro system. Interestingly, 50 pmol of
the COX-2 USE 3 oligoribonucleotide speciﬁcally inhibited
polyadenylation to <10% of the control reaction (Figure 5B,
upper panel). This amount is similar to other USE oligoribo-
nucleotide inhibition reactions (64,66). The non-speciﬁc oligo
did not inhibit in vitro polyadenylation (Figure 5B, lower
panel). In vitro polyadenylation of a non-USE containing
polyadenylation signal, AAV, was also not inhibited by the
addition of the COX-2 USE 3 at similar concentrations as
expected (Figure 5C). Polyadenylation of AAV was also not
affected by addition of the non-speciﬁc oligonucleotides as
expected (Figure 5C). Taken together, these data demonstrate
that the COX-2 USE 3 oligoribonucleotide speciﬁcally binds
and sequesters a putative common factor(s) important for
polyadenylation, and suggest that the similarity to the SV40
USE motifs is functionally signiﬁcant.
DISCUSSION
Polyadenylation is a useful and underexplored mechanism
of regulating gene expression, and this regulation is partially
implied by the complex nature of this process. Alternative
polyadenylation can generate mature transcripts that only dif-
fer in their 30 ends. Efﬁciency of processing is another level
at which regulation can occur, since most pre-mRNAs in the
cell are not efﬁciently processed, and therefore, even small
changes in the overall processing efﬁciency of a particular
pre-mRNA may have a great effect on ultimate protein levels.
Experimental evidence has demonstrated that poly(A) signal
strength directly inﬂuences the amount of mature, exported
mRNA (84,85).
Figure 3. Invivo polyadenylation assaysdemonstratethe relativestrengthof the COX-2proximaland distal polyadenylationsignals. (A) Schematicrepresentation
ofthepCbSreporterconstructusedintheinvivopolyadenylationassay.Therelativepositionofeachpolyadenylationsignalisdiagramed.TheBGHpolyadenylation
signal is always located at poly(A) site 2. The proximal and distal constructs have those respective sequences cloned into poly(A) site 1. Only the pCbS-proximal-
distal-BGH and pCbS-proximal-distal constructs vary from this scheme. (B) Representative RNase protection data for in vivo polyadenylation assays using these
constructs.Lane1, sizemarkers frompBR322cutwith MspIand50 end labeledwith[g-
32P]ATPasindicated;lane 2,undigestedprobe;lane 3,pCbS emptyvector;
lanes4and5,COX-2constructsinpCbSasindicatedabovethelane;lane6,undigestedprobe;andlane7,pCbS-proximal-distal.(C)pCbS-proximalwastransfected
into HeLa (closed bars) or MDA-MB-231 cells (gray bars), RNA was isolated after 24 h, and RNase protection assays were performed. Quantification of three
independentexperimentsisshownhere.Constructsareshownonthex-axis;percentuseofeithertheproximalorBGHisshownonthey-axis.Thepercentutilization
was calculated based on the ratio of each signal being utilized within each experiment. Error bars represent SD. All P-values are <1.9 · 10
 13.( D)p C bS-distal was
transfected into HeLa (closed bars) or MDA-MB-231 cells (gray bars), RNA was isolated after 24 h, and RNase protection assays were performed. Quantification
of three independent experiments is shown here. Constructs are shown on the x-axis; percent use either the distal or BGH polyadenylation signal is shown on the
y-axis. The percent utilization was calculated based on the ratio of each signal being utilized within each experiment. Error bars represent SD. All P-values are
<0.0008. (E)p C bS-proximal-distal was transfected into HeLa (closed bars) or MDA-MB-231 cells (gray bars), RNA was isolated after 24 h, and RNase protection
assays were performed.Quantification of three independent experiments is shownhere. Percent use of either the proximal or distal polyadenylation signal is shown
on the y-axis. The percent utilization was calculated based on the ratio of each signal being utilized within each experiment. Error bars represent SD. All P-values
were <0.005.
Nucleic Acids Research, 2005, Vol. 33, No. 8 2573Our objective in this study was to accurately deﬁne and
characterize alternative polyadenylation as it applied to the
human COX-2 30-UTR. Interestingly, the size and scheme of
the 30-UTR is conserved among human, chimpanzee, mouse
and rat COX-2 genes, along with the two polyadenylation
signals, suggesting that the importance of alternative poly-
adenylation plays a key regulatory function (B. Tian,
H. Zhang, and C. S. Lutz, unpublished data). Indeed, the
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2574 Nucleic Acids Research, 2005, Vol. 33, No. 8sequences forUSEs 1and2are exactmatchesinthe 30-UTR of
mouse COX-2 homolog (B. Tian, H. Zhang, and C. S. Lutz,
unpublished data). Choice of a particular polyadenylation sig-
nal may result in mRNAs with different stability or different
translation efﬁciency, which has direct consequences for how
much protein product is ultimately produced. Therefore, poly-
adenylation signal choice can be a key step in mRNA matura-
tion. Our work examined the relative strength and composition
of the COX-2 proximal and distal polyadenylation signals. We
have shown that the COX-2 proximal and COX-2 distal
polyadenylation signals are utilized in an in vivo polyadenyla-
tion assay. We further demonstrated that the use of these
COX-2 polyadenylation signals is regulated in a tissue-
speciﬁc manner. We propose that while basal polyadenylation
of these signals does occur experimentally in cell types that
do not normally express COX-2 mRNA (HeLa and MDA-
MB-231), the cell-type speciﬁc utilization of COX-2 proximal
anddistalpolyadenylationsignalsmayrequireadditionalasyet
unidentiﬁed factors.
Additionally, we have demonstrated that a suboptimal
CPSF binding site (AUUAAA) is truly weaker than the canon-
ical CPSF binding site, AAUAAA. Taken together, the data
suggest a working hypothesis, shown in Figure 6, for poly-
adenylation signal choice, as well as for possible correlations
between polyadenylation signal choice and resulting mRNA
stability as postulated (81).
Our model (Figure 6) suggests that use of the COX-2
proximal polyadenylation signal results in a shorter mRNA,
while use of the COX-2 distal polyadenylation signal results
in a longer mRNA. Use of the proximal polyadenylation signal
would exclude a portion of the 30-UTR, which may contain
important regulatory elements, for example, elements that
regulate mRNA stability. The best characterized 30-UTR
sequences that cause mRNA instability are the AREs found
in many short-lived mRNAs such as cytokines, growth
factors and proto-oncogenes (72,73). The 30-UTR of COX-2
iscomplexandhasmanyAREs(Figure1).Currently,datainthe
literature conﬂict with regard to which form of COX-2 is more
stable. It has been shown that removal of some sequences
upstream of the COX-2 proximal polyadenylation
signal containing some of the AREs confers increased stability
to a heterologous reporter (86), while other data have
shown that this same region can transfer instability to a
heterologous reporter (87,88). Additionally, the longer
COX-2 mRNA has been reported to be the more unstable
form as revealed by northern blotting of the COX-2 mRNA
whiletheshorterformisgenerallythoughttobethemorestable
form(81).Whileourstudyhasnotaddressedthesequestionsof
stability directly, our study underscores the importance of
understanding how alternative polyadenylation of COX-2
is regulated.
We have also demonstrated here that the USEs present in
the suboptimal COX-2 proximal polyadenylation signal have
a signiﬁcant effect on in vivo polyadenylation of that signal,
since mutation or deletion of the USEs has a substantial effect
(Figure 4C). We suggest that the presence of the USEs in the
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Nucleic Acids Research, 2005, Vol. 33, No. 8 2575COX-2 proximal polyadenylation signal ensure its usage,
possibly by supporting and enhancing assembly of the basal
polyadenylation machinery on the polyadenylation signal, or
by serving as a trans-acting factor binding site which may
recruit or enhance interactions with the basal polyadenylation
machinery. These explanations are not mutually exclusive.
Additionally, tissue-speciﬁc factors may be involved since we
have shown tissue-speciﬁc utilization occurs at the COX-2
proximal polyadenylation signal. These details remain to be
explored.
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